SC 13D/A - IGC Pharma, Inc. (0001326205) (Subject)

SC 13D - IGC Pharma, Inc. (0001326205) (Subject)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

3 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

3 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

https://x.com/POTUS/status/1813565568454127970

Alliance Global Partners analyst James Molloy initiates coverage on IGC Pharma (AMEX:IGC) with a Buy rating and announces Price Target of $3.5.

https://www.marijuanamoment.net/gop-congressional-committee-approves-bill-to-block-marijuana-rescheduling-while-rejecting-state-cannabis-protections-amendment/

- Preliminary Analysis confirms the presence of TGR-63 in brain tissue and shows no adverse effects. -IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced preclinical data demonstrating TGR-63's potential as an effective treatment for Alzheimer's disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer's murine models both indicate that TGR-63 has the potential to cross the blood-brain barrier in humans. These findings build on earlier results demonstrating TGR-63's efficacy in reducing amyloid plaque in Alzheimer's mouse models.

https://www.marijuanamoment.net/california-legislature-approves-bill-to-break-psychedelics-research-logjam-sending-it-to-governor/

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousand which beat the analyst consensus estimate of $193.000 thousand by 52.85 percent. This is a 77.71 percent increase over sales of $166.000 thousand the same period last year.

Ascendiant Capital analyst Edward Woo reiterates IGC Pharma (AMEX:IGC) with a Buy and maintains $3.25 price target.

Anson Funds agreed to a $2.25 million settlement with the Securities and Exchange Commission (SEC) over a secret relationship with a short seller affecting two cannabis companies. The SEC found that while Anson Funds disclosed its short position strategy to investors, it did not reveal its collaboration with an activist short publisher, which remains undisclosed. The Scheme The SEC detailed that Anson Funds would establish a short position before the release of negative reports by the short seller, reported Bloomberg. These reports often led to a decrease in the target companies’ stock prices, allowing Anson Funds to profit from the drop. The events happened in 2018, and the involved c

Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million. Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million. Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million. IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million. OpGen (NASDAQ:OPGN) shares moved upwards by

10-Q - IGC Pharma, Inc. (0001326205) (Filer)

8-K - IGC Pharma, Inc. (0001326205) (Filer)

144 - IGC Pharma, Inc. (0001326205) (Subject)

10-Q - IGC Pharma, Inc. (0001326205) (Filer)

8-K - IGC Pharma, Inc. (0001326205) (Filer)

DEFA14A - IGC Pharma, Inc. (0001326205) (Filer)

DEF 14A - IGC Pharma, Inc. (0001326205) (Filer)

10-K - IGC Pharma, Inc. (0001326205) (Filer)

EFFECT - IGC Pharma, Inc. (0001326205) (Filer)

8-K - IGC Pharma, Inc. (0001326205) (Filer)

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatme

- Company Expands Phase 2 trial to Canada -POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia.Agitation affects between 40-80% of Alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication.IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties and acts as an inflammasome inhibitor, addressing key pathways involved in th

POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to

IGC-AD1 demonstrates the potential to modify tau and improve spatial memory Data supports the initiation of clinical trials investigating IGC-AD1 as a treatment for Alzheimer's disease IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") today announced data that reinforces the therapeutic potential of IGC-AD1 as a disease-modifying treatment for Alzheimer's disease. The data highlights IGC-AD1's promising effects on tau tangles and spatial memory. These results build on earlier data demonstrating IGC-AD1's potential to reduce amyloid plaque. IGC Pharma's findings from preclinical Alzheimer's cell line studies have revealed IGC-AD1's significant impact on tau pathology. The data s

IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease. Following the FDA's 2023 approval of two groundbreaking anti-amyloid drugs, Donanemab (Eli Lilly) and Lecanemab (Eisai and Biogen), IGC Pharma is poised to make a significant contribution to this critical field with IGC-AD1. The recognition of amyloid-targeted therapies in slowing Alzheimer's progression and improving cognitive function underscores the growing demand for innovative treatments. While the recent drug approvals have been a signific

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla

IGC-1C Targets Tau Protein and GLP-1 Receptor, Offering a Multi-Pathway Approach to Neurodegenerative and Metabolic Disease Treatment IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") today announced preclinical research demonstrating the therapeutic potential of IGC-1C, a novel small-molecule modulator. The findings show that IGC-1C targets tau protein phase separation, presenting new opportunities for addressing multiple pathways in neurodegenerative disease. Additionally, the Company previously announced that IGC-1C along with IGC-1A have been identified by the Company's Artificial Intelligence ("AI") model as potential GLP-1 receptor agonists, offering promise as candidate

- Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies - IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") today announced that the Company's proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agonist, as a result of the Company's state-of-the-art Artificial Intelligence ("AI") modeling. This discovery highlights the versatility of IGC Pharma's drug platforms and marks the Company's potential for strategic expansion to metabolic disorders and weight loss. Identifying IGC-1A as a potential GLP-1 agonist marks a significant milestone for IGC Pharma, presenting a substantial market opportunity and improving patie

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company's Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer's disease. On April 16, 2024, the Company announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. On May 28, 2024, the Comp

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology (IHV), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Terry founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network (PanCAN), and the National

India Globalization Capital, Inc. (NYSE:IGC) announces that the Board has appointed Ms. Claudia Grimaldi as a non-independent Director, effective March 23, 2022. IGC now has 5 directors including a majority who are independent. Ms. Grimaldi has been with IGC for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance, and disclosures. She is currently Vice President, Principal Finance Officer, and Chief Compliance Officer. She is also the Managing Director of Hamsa Biochem SAS, our subsidiary in Colombia, as well as a director of our subsidiary in India. Ms. Grimaldi stated: "I hope to bring diversity of thought and perspective to th

India Globalization Capital, Inc. (NYSE:IGC) is excited to announce that the Board has appointed former Congressman Jim Moran ("Congressman Moran") as an independent Director. IGC is delighted to welcome Congressman Moran to its Board of Directors. Congressman Moran served Virginia's 8th Congressional District for 24 years, where he was known as a "Problem Solver." Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance and Budget committees. He played a leadership role in the areas of defense, health, and the environment. During his 24 years in Congress, C

POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for, and convened on January 11, 2021, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on December 8, 2020 were passed. Only stockholders of record on the record date of November 20, 2020, were entitled to and were being requested to vote. At the Annual Meeting, the following proposals were approved: (i) the election of John E. Lynch to the Company’s Board of Directors; (ii) the proposal to ratify Manohar Chowdhry & Associates (“MCA”) as the Company’s independent registered public account